J. Grebely

发表

The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.

M. Alavi, G. Dore, P. Haber, 2015, The International journal on drug policy.

Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.

J. Grebely, P. Bruggmann, 2015, The International journal on drug policy.

Epidemiology and natural history of HCV infection

G. Dore, J. Grebely, B. Hajarizadeh, 2013, Nature Reviews Gastroenterology &Hepatology.

Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs

Garry Robins, Philippa Pattison, Scott Bowden, 2012, PloS one.

Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection

G. Cooke, G. Dore, C. Orkin, 2020, Hepatology.

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis

G. Dore, A. Poon, J. Amin, 2015, PloS one.

Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.

M. Alavi, G. Dore, L. Degenhardt, 2021, The International journal on drug policy.

Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada.

Nanor Minoyan, M. Sylvestre, E. Fortier, 2021, The International journal on drug policy.

Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.

P. Read, L. Degenhardt, J. Grebely, 2021, Drug and alcohol dependence.

Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study.

M. Alavi, P. Read, A. Milat, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis.

J. Leung, A. Trickey, J. Stone, 2020, The International journal on drug policy.

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study.

C. Stedman, B. Conway, M. Hellard, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada.

Nanor Minoyan, M. Sylvestre, E. Fortier, 2019, Drug and alcohol dependence.

Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.

E. Fortier, J. Bruneau, J. Grebely, 2019, Addiction.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

P. Read, B. Conway, M. Hellard, 2018, The lancet. Gastroenterology & hepatology.

Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada.

J. Raffa, G. Dore, J. Amin, 2013, CMAJ open.

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

B. Conway, J. Raffa, J. Grebely, 2008, Drug and alcohol dependence.

Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan

D. Tyrrell, Jennifer F. Raven, J. Grebely, 2016, Canadian journal of gastroenterology & hepatology.

Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review.

J. Leung, A. Trickey, J. Stone, 2020, Drug and alcohol dependence.

Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents

M. Alavi, J. Raffa, G. Dore, 2014, Liver international : official journal of the International Association for the Study of the Liver.

HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection

R. Kaul, M. Ostrowski, C. Kovacs, 2016, PloS one.

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.

G. Lauer, M. Hellard, G. Dore, 2012, The Lancet. Infectious diseases.

HCV reinfection studies and the door to vaccine development.

G. Dore, J. Grebely, David L. Thomas, 2009, Journal of hepatology.

The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure.

G. Dore, J. Grebely, G. Matthews, 2008, Journal of hepatology.

Hepatitis C virus reinfection in injection drug users

B. Conway, J. Raffa, J. Grebely, 2006, Hepatology.

Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study.

F. Luciani, G. Dore, J. Amin, 2018, The International journal on drug policy.

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005‐2014: The HITS‐p study

F. Luciani, G. Dore, J. Amin, 2017, Journal of viral hepatitis.

COHORT PROFILE Cohort Profile : The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts ( InC 3 ) Study

G. Lauer, M. Hellard, G. Dore, 2014 .

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

G. Lauer, M. Hellard, G. Dore, 2014, Hepatology.

Global statistics on alcohol, tobacco and illicit drug use: 2017 status report

A. Ferrari, G. Giovino, L. Degenhardt, 2018, Addiction.

Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.

J. Lazarus, C. Treloar, J. Bruneau, 2019, The International journal on drug policy.

The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative

A. Mirzazadeh, G. Lauer, M. Hellard, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?

Nanor Minoyan, J. Bruneau, J. Grebely, 2018, Canadian liver journal.

Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration

G. Lauer, M. Hellard, S. Shiboski, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy.

T. Rhodes, M. Hickman, C. Treloar, 2017, The International journal on drug policy.

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

G. Dore, S. Mauss, J. Grebely, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

Brandon D. L. Marshall, O. Pybus, P. Harrigan, 2014, Hepatology.

Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012

Julio S. G. Montaner, G. Dore, B. Marshall, 2014, PloS one.

Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection

J. Kaldor, M. Hellard, G. Dore, 2013, Hepatology.

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

G. Lauer, F. Luciani, M. Hellard, 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

J. Leung, R. Mattick, A. Trickey, 2017, The Lancet. Global health.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

M. Hellard, G. Dore, L. Taylor, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection.

M. Hellard, G. Dore, L. Taylor, 2015, The International journal on drug policy.

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection

J. Kaldor, M. Hellard, G. Dore, 2012, Hepatology.

The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.

A. Mirzazadeh, G. Lauer, M. Hellard, 2016, Drug and alcohol dependence.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

A. de Gottardi, G. Dore, L. Taylor, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study.

J. Amin, M. Falster, L. Degenhardt, 2015, Drug and alcohol dependence.

A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?

J. Leung, R. Mattick, A. Trickey, 2019, The Journal of infectious diseases.

Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.

N. Luhmann, C. Treloar, J. Bruneau, 2019, The International journal on drug policy.

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

G. Dore, L. Taylor, J. Grebely, 2015, Annals of Internal Medicine.

Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis

J. Higgins, P. Vickerman, L. Degenhardt, 2020, Addiction.

The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis.

J. Leung, A. Trickey, J. Stone, 2019, The International journal on drug policy.

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.

G. Dore, J. Grebely, L. Maher, 2017, The International journal on drug policy.

Treatment of acute HCV infection

G. Dore, J. Grebely, G. Matthews, 2011, Nature Reviews Gastroenterology &Hepatology.

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.

G. Dore, P. Vickerman, J. Amin, 2021, The lancet. Gastroenterology & hepatology.

Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

G. Lauer, F. Luciani, M. Hellard, 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Management of acute HCV infection in the era of direct-acting antiviral therapy

G. Dore, J. Grebely, B. Hajarizadeh, 2018, Nature Reviews Gastroenterology & Hepatology.

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

M. Hellard, G. Dore, P. Vickerman, 2013, Hepatology.

Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.

M. Alavi, G. Dore, M. Law, 2019, Journal of hepatology.

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Lisa P. Barrett, L. Taylor, C. Treloar, 2016, CMAJ open.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

V. Wong, D. Booth, T. Berg, 2015, Nature Communications.

Can hepatitis C virus infection be eradicated in people who inject drugs?

G. Dore, J. Grebely, 2014, Antiviral research.

Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study

M. Alavi, P. Hayes, G. Dore, 2018, Journal of viral hepatitis.

Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison

M. Alavi, P. Hayes, G. Dore, 2017 .

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies

G. Dore, S. Zeuzem, G. Foster, 2018, Open forum infectious diseases.

6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection-What are the remaining gaps?

E. Fortier, J. Grebely, S. Sagan, 2018, Canadian liver journal.

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

G. Dore, J. Grebely, A. Lloyd, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study

M. Hellard, C. Aitken, J. George, 2013, PloS one.

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

M. Hellard, G. Dore, P. Vickerman, 2013, Hepatology.

A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events.

Andrea D. Olmstead, P. Harrigan, J. Montaner, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Target Population : patients with acute hepatitis C virus infection Setting :

G. Dore, J. Grebely, B. Hajarizadeh, 2015 .

Case definitions for acute hepatitis C virus infection: a systematic review.

G. Dore, J. Grebely, B. Hajarizadeh, 2012, Journal of hepatology.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

J. Lazarus, R. Marinho, S. Olafsson, 2018, The lancet. Gastroenterology & hepatology.

Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

G. Dore, J. Grebely, A. Lloyd, 2016, The lancet. Gastroenterology & hepatology.

Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.

G. Dore, M. Micallef, A. Dunlop, 2015, The International journal on drug policy.

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.

T. Asselah, B. Conway, G. Dore, 2019, Drug and alcohol dependence.

Understanding facilitators and barriers of direct‐acting antiviral therapy for hepatitis C virus infection in prison

G. Dore, C. Treloar, J. Grebely, 2018, Journal of viral hepatitis.

Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection

M. Alavi, J. Kaldor, M. Hellard, 2012, Journal of gastroenterology and hepatology.

Frequency of injecting among people who inject drugs: A systematic review and meta-analysis.

J. Leung, A. Trickey, J. Stone, 2019, The International journal on drug policy.

The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.

M. Hellard, C. Aitken, G. Dore, 2012, The Journal of infectious diseases.

Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.

G. Dore, J. Grebely, B. Hajarizadeh, 2020, The Journal of infectious diseases.

Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.

G. Dore, J. Grebely, L. Maher, 2019, Journal of hepatology.

Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study

G. Dore, J. Grebely, G. Cloherty, 2019, Journal of viral hepatitis.

Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?

J. Rockstroh, G. Dore, J. Grebely, 2017, Journal of the International AIDS Society.

Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia.

M. Alavi, G. Dore, P. Haber, 2017, Journal of addiction medicine.

Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.

M. Alavi, G. Dore, P. Haber, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

that may be Markov-chain Monte Carlo analysis of observational study data.

E. McBryde, J. Grebely, R. Sacks-Davis, 2014 .

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.

P. Read, M. Hellard, J. Rockstroh, 2021, Journal of hepatology.

Phosphatidylcholines as regulators of glucose and lipid homeostasis: Promises and potential risks

G. Dore, J. Grebely, S. Hohenester, 2011, Hepatology.

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Andrea D. Olmstead, O. Pybus, P. Harrigan, 2016, Journal of hepatology.

Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.

J. Kaldor, M. Hellard, G. Dore, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.

J. Lazarus, J. Pawlotsky, G. Dore, 2018, Journal of hepatology.

Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: Findings from a cross-sectional study in three Australian cities.

J. Bell, M. Farrell, R. Bruno, 2020, Addiction.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

G. Dore, J. George, J. Grebely, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing.

Andrea D. Olmstead, A. Poon, P. Tang, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.

Josephine G. Walker, J. Leung, M. May, 2019, The lancet. Gastroenterology & hepatology.

Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative

A. Mirzazadeh, G. Lauer, M. Hellard, 2016, Open forum infectious diseases.

HCV infection: findings from the InC3 Collaborative

A. Mirzazadeh, M. Hellard, J. Bruneau, 2016 .

Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort

M. Hellard, G. Dore, H. Wedemeyer, 2015, Journal of viral hepatitis.

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Todd M. Allen, M. Hellard, G. Dore, 2015, The Journal of infectious diseases.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

R. Geskus, B. Grady, J. Amin, 2015, Journal of viral hepatitis.

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

R. Geskus, M. Hellard, B. Grady, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Dynamics of HCV RNA levels during acute hepatitis C virus infection

J. Kaldor, M. Hellard, G. Dore, 2014, Journal of medical virology.

Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection

J. Kaldor, D. Booth, M. Hellard, 2010, Hepatology.

Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users.

B. Conway, J. Raffa, J. Grebely, 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective.

C. Treloar, J. Grebely, A. Marshall, 2022, The International journal on drug policy.

Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.

M. Alavi, G. Dore, M. Law, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.

C. Stedman, P. Read, B. Conway, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs

J. Leung, H. Razavi, R. Mattick, 2018, Addiction.

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

G. Dore, J. Grebely, B. Hajarizadeh, 2017, Nature Reviews Gastroenterology & Hepatology.

Lower life expectancy among people with an HCV notification: a population‐based linkage study

M. Alavi, M. Law, J. Amin, 2014, Journal of viral hepatitis.

Treatment of HCV in persons who inject drugs: Treatment as prevention

G. Dore, J. Grebely, 2017, Clinical liver disease.

Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies

M. Hellard, G. Dore, K. Petoumenos, 2016, Antiviral therapy.

Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs.

G. Dore, J. Grebely, P. Bruggmann, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.

B. Conway, J. Grebely, R. Hilsden, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs.

D. De Angelis, G. Dore, L. Degenhardt, 2015, The International journal on drug policy.

Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment.

M. Alavi, V. Wiseman, G. Dore, 2022, Drug and alcohol dependence.

Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.

G. Dore, J. Grebely, G. Matthews, 2020, The Journal of infectious diseases.

Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.

G. Dore, M. Hickman, J. Bruneau, 2017, Journal of hepatology.

Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis.

J. Leung, L. Degenhardt, J. Grebely, 2019, Drug and alcohol dependence.

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia

R. Bruno, S. Nielsen, B. Larance, 2019, Addiction.

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

Jisoo A. Kwon, M. Alavi, R. Guy, 2021, PloS one.

Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study

Jisoo A. Kwon, R. Guy, H. Razavi, 2018, Journal of viral hepatitis.

Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe

J. Lazarus, R. Marinho, S. Olafsson, 2017 .

Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents

G. Lauer, F. Luciani, M. Hellard, 2017, Journal of viral hepatitis.

Global patterns of opioid use and dependence: Population harms, interventions, and future action

Graeme Henderson, A. Rahimi-Movaghar, F. Altice, 2019 .

A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

R. A. Bull, R. Bull, K. Scheffler, 2017, Journal of viral hepatitis.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

C. Stedman, B. Conway, M. Hellard, 2018, The International journal on drug policy.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

T. Berg, G. Dore, H. Wedemeyer, 2018, Open forum infectious diseases.

Recognizing and preventing death from compensated cirrhosis in the community

J. Talwalkar, J. Grebely, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support

B. Conway, J. Raffa, J. Grebely, 2010, European journal of gastroenterology & hepatology.

P080: Characterizing hepatitis C virus transmission dynamics using molecular phylogenetic‐based methods

P. Harrigan, J. Joy, Y. Khudyakov, 2015 .

Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs.

J. Lazarus, C. Treloar, J. Grebely, 2021, The International journal on drug policy.

Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn

G. Dore, J. Grebely, A. Lloyd, 2014, Hepatology.

The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.

M. Alavi, P. Hayes, G. Dore, 2017, Journal of hepatology.

Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C

F. Luciani, M. Hellard, G. Dore, 2015, Antiviral therapy.

Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia

G. Dore, C. Treloar, J. Grebely, 2011, Journal of viral hepatitis.

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.

M. Alavi, J. Havens, A. Rahimi-Movaghar, 2021, The lancet. Psychiatry.

Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.

L. Degenhardt, N. Janjua, J. Bruneau, 2019, American journal of public health.

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs.

G. Dore, J. Grebely, M. Martinello, 2018, Infectious disease clinics of North America.

Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs.

T. Rhodes, G. Dore, C. Treloar, 2015, The International journal on drug policy.

The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.

D. Tyrrell, M. Houghton, Jennifer F. Raven, 2014, Canadian journal of gastroenterology & hepatology.

Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience.

C. Treloar, J. Grebely, A. Marshall, 2019, Drug and alcohol dependence.

Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study.

J. Grebely, A. Kastelic, A. Litwin, 2019, The International journal on drug policy.

Delivery of treatment for hepatitis C virus infection in the primary care setting

M. Alavi, G. Dore, A. Balcomb, 2014, European journal of gastroenterology & hepatology.

Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011

H. Wand, G. Dore, J. Grebely, 2014, Journal of viral hepatitis.

Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.

G. Dore, L. Taylor, Megan Oser, 2013, The Journal of infectious diseases.

Management of HCV and HIV infections among people who inject drugs.

J. Grebely, M. Tyndall, 2011, Current opinion in HIV and AIDS.

Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

G. Dore, L. Taylor, B. Haire, 2015, Journal of hepatology.

Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study.

G. Dore, J. Grebely, B. Hajarizadeh, 2020, Sexual health.

HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype

G. Dore, S. Hutchinson, J. Grebely, 2018, Journal of medical virology.

HCV reinfection incidence among individuals treated for recent infection

G. Dore, K. Petoumenos, E. Gane, 2017, Journal of viral hepatitis.

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

G. Dore, J. Grebely, B. Hajarizadeh, 2017, Current HIV/AIDS Reports.

The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)

Z. Butt, N. Janjua, J. Grebely, 2016, EBioMedicine.

889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION

J. Kaldor, M. Hellard, G. Dore, 2012 .

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Gamal Esmat, Rui Tato Marinho, Mel Krajden, 2017, The lancet. Gastroenterology & hepatology.

Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review.

M. Hellard, J. Grebely, R. Sacks-Davis, 2012, The International journal on drug policy.

The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.

Julio S. G. Montaner, E. Wood, T. Kerr, 2014, Addiction.

Cure and Control: What Will It Take to Eliminate HCV?

G. Dore, J. Grebely, B. Hajarizadeh, 2019, Topics in Medicinal Chemistry.

A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015

M. Hellard, G. Dore, D. Shaw, 2019, Journal of the International AIDS Society.

Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.

J. Kaldor, M. Hellard, G. Dore, 2010, Gastroenterology.

Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.

G. Dore, J. Grebely, B. Hajarizadeh, 2020, The Journal of infectious diseases.

Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots.

J. Grebely, T. Applegate, A. Carrera, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study

M. Hellard, B. Grady, G. Dore, 2015, PloS one.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

Kathy Petoumenos, Margaret Hellard, Jason Grebely, 2016, Hepatology.

Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis

J. Leung, R. Mattick, A. Trickey, 2019, The Lancet. Global health.

Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection

R. Kaul, G. Dore, H. Janssen, 2022, Journal of viral hepatitis.

Mixed HCV infection and reinfection in people who inject drugs—impact on therapy

Jason Grebely, Andrew R. Lloyd, G. Dore, 2015, Nature Reviews Gastroenterology &Hepatology.

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

F. Luciani, M. Hellard, G. Dore, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Protease and Polymerase Inhibitors for the Treatment of Hepatitis C Virus Infection

G. Dore, J. Grebely, 2010 .

Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar

J. Grebely, T. Applegate, S. Phyu, 2023, Viruses.

The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.

M. Mclean, B. Conway, J. Raffa, 2007, Drug and alcohol dependence.

Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study

G. Dore, P. Vickerman, J. Amin, 2018 .

Current Approaches to HCV Infection in Current and Former Injection Drug Users

B. Conway, J. Grebely, F. Duncan, 2008, Journal of addictive diseases.

Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.

J. Ward, L. Degenhardt, G. Fontaine, 2022, The lancet. Gastroenterology & hepatology.

Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay

G. Dore, D. Persing, J. Amin, 2018, The Journal of infectious diseases.

Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis

J. Grebely, J. Feld, T. Applegate, 2017, Expert review of molecular diagnostics.

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.

B. Conway, J. Raffa, J. Grebely, 2007, The International journal on drug policy.

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment

F. Luciani, R. Bull, J. Grebely, 2017, Scientific Reports.

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

B. Conway, F. Altice, G. Dore, 2017 .

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

A. Mangia, G. Dore, S. Zeuzem, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

D. Nickle, B. Conway, F. Altice, 2016, Annals of internal medicine.

Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.

G. Dore, M. Micallef, C. Day, 2015, The International journal on drug policy.

Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.

C. Treloar, J. Grebely, Y. Lavis, 2011, Drug and alcohol dependence.

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Jisoo A. Kwon, V. Wong, F. Tacke, 2022, The lancet. Gastroenterology & hepatology.

Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples.

G. Dore, J. Amin, J. Grebely, 2018, The Journal of molecular diagnostics : JMD.

Global patterns of opioid use and dependence: harms to populations, interventions, and future action

Graeme Henderson, A. Rahimi-Movaghar, F. Altice, 2019, The Lancet.

Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.

G. Dore, C. Treloar, J. Grebely, 2018, The International journal on drug policy.

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review

J. Leung, R. Mattick, J. Strang, 2017, The Lancet. Global health.

Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.

J. Grebely, E. Cunningham, C. Fraser, 2021, The International journal on drug policy.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

J. Lazarus, M. Hellard, G. Dore, 2017, The International journal on drug policy.

Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.

J. Leung, Y. Bao, L. Degenhardt, 2019, The International journal on drug policy.

Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study

P. Read, G. Dore, J. Grebely, 2022, Viruses.

People engaged in opioid agonist treatment as a counterpublic during the COVID‐19 pandemic in Australia: A qualitative study

C. Treloar, J. Grebely, A. Conway, 2022, Drug and alcohol review.

Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review

F. Ceccherini‐Silberstein, V. Miller, J. Pawlotsky, 2017, Hepatology communications.

IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis

D. Booth, T. Berg, A. Mangia, 2017, Nature Genetics.

A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections.

J. Joy, G. Dore, A. Poon, 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Genomic variability of within‐host hepatitis C variants in acute infection

G. Lauer, F. Luciani, M. Hellard, 2019, Journal of viral hepatitis.

Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

G. Lauer, F. Luciani, M. Hellard, 2016, The Journal of infectious diseases.

Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users

Fiona Duncan, Chris Fraser, Jason Grebely, 2007, Journal of gastroenterology and hepatology.

Sequencing of the Hepatitis C Virus: A Systematic Review

P. Simmonds, G. Dore, J. Grebely, 2013, PloS one.

Phylogenetic analysis of full‐length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study

G. Lauer, F. Luciani, M. Hellard, 2017, Journal of viral hepatitis.

Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: A population‐level tool for incidence estimation

Mel Krajden, Darrel Cook, Vincent Montoya, 2015, Hepatology.

The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination.

J. Lazarus, H. Razavi, G. Cooke, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis

M. Alavi, G. Dore, J. Grebely, 2021, Journal of viral hepatitis.

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

J. Lazarus, M. Hellard, J. Dillon, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.

G. Dore, J. Grebely, L. Maher, 2017, The International journal on drug policy.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.

L. Degenhardt, J. Grebely, G. Campbell, 2021, JAMA psychiatry.

Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study

G. Dore, C. Treloar, J. Grebely, 2014, Journal of viral hepatitis.

Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.

M. Hellard, S. Hutchinson, J. Grebely, 2014, The International journal on drug policy.

A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study

M. Alavi, P. Read, A. Milat, 2022, Viruses.

Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study

P. Read, G. Dore, M. Weltman, 2019, Journal of viral hepatitis.

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.

G. Dore, M. Law, J. Grebely, 2018, The lancet. Gastroenterology & hepatology.

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

M. Hellard, G. Dore, S. Hutchinson, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C‐SCOPE Study

J. Grebely, A. Kastelic, A. Litwin, 2019, Journal of viral hepatitis.

Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment

M. Alavi, H. Razavi, G. Dore, 2017, Journal of gastroenterology and hepatology.

Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.

M. Alavi, G. Dore, M. Weltman, 2016, Addiction.

Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents

J. Raffa, T. Kerr, J. Grebely, 2009, Journal of viral hepatitis.

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.

G. Dore, M. Law, M. Hickman, 2019, Journal of hepatology.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

B. Conway, M. Hellard, G. Dore, 2017, The International journal on drug policy.

Title: Reinfection with hepatitis C virus following sustained virological response in injection drug users Running title: HCV reinfection following SVR in IDUs

Raffa, B. Conway, G. Dore, 2016 .

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

J. Montaner, E. Wood, I. Rozada, 2015, PloS one.

Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study

M. Alavi, G. Dore, P. Haber, 2015, Journal of viral hepatitis.

Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.

G. Dore, T. Collie, M. Micallef, 2015, The International journal on drug policy.

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

M. Alavi, J. Kaldor, M. Hellard, 2015, The International journal on drug policy.

Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.

G. Dore, C. Treloar, J. Grebely, 2013, Drug and alcohol dependence.

The Second Canadian Symposium on hepatitis C virus: a call to action.

D. Tyrrell, M. Houghton, Jennifer F. Raven, 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.

G. Dore, C. Treloar, J. Grebely, 2012, Drug and alcohol review.

Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity.

G. Dore, J. Grebely, 2011, The Journal of infectious diseases.

Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents

J. Raffa, G. Dore, T. Kerr, 2011, Journal of viral hepatitis.

Reinfection with hepatitis C virus following sustained virological response in injection drug users

B. Conway, J. Raffa, G. Dore, 2009, Journal of gastroenterology and hepatology.

Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

J. Kaldor, G. Dore, K. Petoumenos, 2010, Drug and alcohol dependence.

Reinfection with hepatitis C virus following sustained virological response in injection drug users: HCV reinfection following SVR in IDUs

B. Conway, J. Raffa, G. Dore, 2009 .

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection

M. Hellard, G. Dore, J. Amin, 2016, BMC Infectious Diseases.

What Is Killing People with Hepatitis C Virus Infection?

G. Dore, J. Grebely, Gregory Dore1, 2011, Seminars in liver disease.

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

P. Read, G. Dore, M. Weltman, 2020, Health science reports.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

B. Conway, M. Hellard, G. Dore, 2017, The International journal on drug policy.

Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis.

P. Read, G. Dore, P. Vickerman, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study

P. Read, G. Dore, C. Treloar, 2019, Journal of viral hepatitis.

'I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study.

G. Dore, C. Treloar, J. Grebely, 2017, The International journal on drug policy.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

G. Dore, D. Persing, J. Amin, 2017, The lancet. Gastroenterology & hepatology.

Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs.

T. Rhodes, G. Dore, C. Treloar, 2015, The International journal on drug policy.

New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series.

P. Vickerman, S. Hutchinson, L. Degenhardt, 2017, Addiction.

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

J. Cairns, G. Dore, P. Vickerman, 2016, Journal of hepatology.

Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they?

J. Grebely, M. Martinello, 2020 .

COHORT PROFILE Cohort Profile : The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts ( InC 3 ) Study

G. Lauer, M. Hellard, G. Dore, 2014 .

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.

P. Read, B. Conway, M. Hellard, 2018, The International journal on drug policy.

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

B. Conway, M. Hellard, G. Dore, 2017, BMC Infectious Diseases.

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.

M. Alavi, J. Kaldor, M. Hellard, 2011, Journal of hepatology.

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

J. Kaldor, M. Hellard, G. Dore, 2010 .

Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

E. Asante-Appiah, B. Conway, F. Altice, 2022, Annals of Internal Medicine.

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection

G. Cooke, G. Dore, C. Orkin, 2018, Journal of viral hepatitis.

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

F. Ceccherini‐Silberstein, J. Pawlotsky, J. Lennerstrand, 2021, Viruses.

Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake

Jisoo A. Kwon, R. Guy, H. Razavi, 2018 .

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection

J. Kaldor, M. Hellard, G. Dore, 2012, AIDS.

Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia

G. Dore, J. Grebely, B. Hajarizadeh, 2018, Journal of viral hepatitis.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

T. Berg, A. Mangia, J. Nattermann, 2019, Scientific Reports.

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

G. Dore, M. Law, J. Amin, 2017, Journal of hepatology.

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

G. Dore, J. Grebely, B. Hajarizadeh, 2015, The Journal of molecular diagnostics : JMD.

Association Between Female Sex , IL 28 B Genotype , but Also DQB 1 * 0301 Allele and the Outcome of Acute Hepatitis C Virus Infection

G. Dore, J. Grebely, A. Lloyd, 2014 .

Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection.

J. Stone, P. Vickerman, M. Hickman, 2021, The International journal on drug policy.

Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data

Peter Vickerman, Margaret Hellard, Rachel Sacks-Davis, 2015, Journal of The Royal Society Interface.

A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective.

B. Conway, J. Grebely, H. Tossonian, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

COVID-19 and the health of people who use drugs: What is and what could be?

T. Rhodes, M. Cerdá, J. Grebely, 2020, International Journal of Drug Policy.

Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.

G. Dore, C. Treloar, J. Grebely, 2020, The International journal on drug policy.

Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012

M. Alavi, G. Dore, M. Law, 2018, BMC Infectious Diseases.

The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international comparison study

M. Alavi, P. Hayes, G. Dore, 2017 .

Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.

M. Alavi, G. Dore, M. Law, 2016, Journal of hepatology.

An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.

M. Alavi, R. Malekzadeh, H. Poustchi, 2019, The International journal on drug policy.

The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study

Josephine G. Walker, J. Leung, M. May, 2019 .

Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.

M. Alavi, G. Dore, M. Law, 2015, Journal of hepatology.

A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs

M. Hellard, G. Dore, J. Bruneau, 2015, Journal of Epidemiology & Community Health.

The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments

G. Dore, J. Grebely, B. Hajarizadeh, 2017 .

Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia

M. Alavi, G. Dore, J. Grebely, 2022, Viruses.

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach

P. Harrigan, J. Montaner, J. Raghwani, 2018, Journal of viral hepatitis.

"That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.

C. Treloar, J. Grebely, A. Lloyd, 2021, The International journal on drug policy.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

T. Berg, A. Mangia, J. Nattermann, 2016, Nature Communications.

Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: A modelling study

Josephine G. Walker, J. Leung, M. May, 2019, Journal of viral hepatitis.

"You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.

A. Milat, G. Dore, C. Treloar, 2022, The International journal on drug policy.

Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)

N. Martin, T. Butler, C. Treloar, 2021, Harm Reduction Journal.

Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model

Jisoo A. Kwon, D. Schanzer, H. Razavi, 2020, JAMA network open.

Associations between the prevalence of chronic hepatitis B among people who inject drugs and country‐level characteristics: An ecological analysis

J. Leung, A. Trickey, L. Degenhardt, 2023, Drug and alcohol review.

Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014)

M. Alavi, G. Dore, M. Law, 2017, Hepatology communications.

Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

M. Alavi, G. Dore, M. Law, 2016, Journal of hepatology.

Prescribing of direct‐acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program

G. Dore, A. Balcomb, J. Grebely, 2021, The Medical journal of Australia.

Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study

G. Dore, J. Stone, A. Lim, 2022, Liver international : official journal of the International Association for the Study of the Liver.

'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.

L. Degenhardt, C. Treloar, J. Grebely, 2023, The International journal on drug policy.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

G. Dore, S. Nielsen, B. Larance, 2021, The International journal on drug policy.

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

G. Dore, S. Nielsen, B. Larance, 2020, BMJ Open.

Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.

J. Leung, G. Dore, P. Vickerman, 2023, The Lancet. Global health.

Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.

J. Ward, G. Dore, P. Vickerman, 2022, The International journal on drug policy.

Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.

M. Alavi, P. Read, G. Dore, 2022, The International journal on drug policy.

Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation.

C. Treloar, J. Grebely, A. Marshall, 2020, The International journal on drug policy.

Creating an environment for equitable access to direct‐acting antiviral therapy for people who inject drugs with hepatitis C

G. Dore, J. Grebely, H. Valerio, 2020, Liver international (Print).

Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.

J. Grebely, E. Cunningham, C. Fraser, 2019, The International journal on drug policy.

Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.

J. Leung, P. Vickerman, L. Degenhardt, 2023, The Lancet. Global health.

Estimating the number of people who inject drugs in Australia

R. Guy, G. Dore, L. Degenhardt, 2017, BMC Public Health.

Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons

G. Dore, J. Stone, A. Lim, 2021, Hepatology.

Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence.

J. Leung, R. Mattick, A. Trickey, 2020, The International journal on drug policy.

Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.

B. Conway, G. Dore, J. Dillon, 2019, The International journal on drug policy.

Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.

G. Lauer, H. Wand, M. Hellard, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?

L. Degenhardt, M. Hickman, J. Grebely, 2018, Addiction.

Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.

M. Alavi, P. Read, A. Milat, 2022, The International journal on drug policy.

Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia.

J. Grebely, P. Dietze, A. Peacock, 2021, Drug and alcohol review.

Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.

C. Stedman, P. Read, B. Conway, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.

P. Harrigan, J. Montaner, B. Marshall, 2015, Drug and alcohol dependence.

A global systematic review of hepatitis C elimination efforts through micro-elimination.

J. Ward, J. Lazarus, G. Cooke, 2022, Seminars in liver disease.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection

M. Hellard, G. Dore, J. Amin, 2016, Virology Journal.

The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There".

J. Grebely, S. Sagan, J. Feld, 2018, Canadian liver journal.

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C

J. Grebely, S. Sagan, S. Macparland, 2016, Canadian journal of gastroenterology & hepatology.

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

B. Conway, F. Altice, G. Dore, 2016 .

Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools

G. Dore, J. Amin, J. Grebely, 2017 .

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.

B. Conway, G. Dore, G. Foster, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The 8th Canadian Symposium on Hepatitis C virus: "Improving diagnosis and linkage to care".

G. Sebastiani, J. Grebely, S. Sagan, 2020, Canadian liver journal.

60 DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN

J. Kaldor, M. Hellard, G. Dore, 2010 .

Global elimination of hepatitis C virus by 2030: why not?

M. Alavi, G. Dore, J. Grebely, 2020, Nature Medicine.

Hepatitis C: A Canadian perspective.

J. Grebely, J. Feld, N. Shoukry, 2018, Canadian liver journal.

Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.

P. Read, G. Dore, J. Grebely, 2023, The International journal on drug policy.

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Dao Sen Wang, M. Poljak, F. Ceccherini‐Silberstein, 2022, JHEP reports : innovation in hepatology.

Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis

Jisoo A. Kwon, V. Wiseman, G. Dore, 2023, Social Science Research Network.

A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia.

G. Dore, J. Grebely, A. Lloyd, 2023, The Lancet Gastroenterology and Hepatology.

Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.

J. Pawlotsky, G. Dore, J. Grebely, 2022, Journal of Infectious Diseases.

Global elimination of hepatitis C virus by 2030: why not?

M. Alavi, G. Dore, J. Grebely, 2020, Nature Medicine.

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort

M. Alavi, M. Hellard, G. Dore, 2016, PloS one.

No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression

G. Dore, M. Law, J. Amin, 2017 .

Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.

B. Conway, J. Raffa, J. Grebely, 2008, Journal of Acquired Immune Deficiency Syndromes.

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

R. Chung, G. Dore, E. Verna, 2017 .

Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

P. Read, B. Conway, M. Hellard, 2017 .

578 Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada

B. Conway, J. Raffa, J. Grebely, 2006 .

Optimisation of rural clinical and haematological indicators of diabetes in pregnancy (ORCHID) to improve detection of risk for adverse birth outcomes: from addressing glycolysis to implementing novel tests for detecting hyperglycaemia in pregnancy

J. Grebely, M. Shephard, S. Matthews, 2023, Pathology.

“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic

G. Dore, L. Degenhardt, C. Treloar, 2023, International Journal of Drug Policy.

Hepatitis C: Enhancing treatment for hepatitis C among drug users

G. Dore, J. Grebely, 2011, Nature Reviews Gastroenterology &Hepatology.

Systematic approach to the treatment of HCV infection in injection drug users: where are we now?

B. Conway, J. Raffa, J. Grebely, 2009 .

Time for a systematic approach to the treatment of hepatitis C virus infection in injection drug users

B. Conway, J. Grebely, F. Duncan, 2006 .

Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?

B. Grady, G. Dore, J. Grebely, 2014, Hepatology.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection

M. Hellard, G. Dore, J. Amin, 2016, Virology Journal.

Primary drug resistance in antiretroviral-naïve injection drug users.

M. Mclean, B. Conway, J. Raffa, 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study.

M. Alavi, G. Dore, J. Amin, 2023, Drug and alcohol review.

Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies

M. Hellard, G. Dore, K. Petoumenos, 2016, Antiviral therapy.

Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection

G. Dore, K. Petoumenos, J. Grebely, 2010, Journal of viral hepatitis.

Hepatitis C Virus Treatment and Persons Who Inject Drugs

G. Dore, L. Taylor, J. Grebely, 2016, Annals of Internal Medicine.

Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection

J. Kaldor, M. Hellard, G. Dore, 2013, PloS one.

V. Wiseman, G. Dore, A. Miners, 2023, Quality of Life Research.

Addressing reimbursement disparities for direct‐acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all

J. Grebely, A. Litwin, G. Dore, 2016, Journal of viral hepatitis.

Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program

M. Mclean, B. Conway, J. Raffa, 2007, Journal of acquired immune deficiency syndromes.

B. Conway, F. Altice, E. Gane, 2022, Journal of addictive diseases.

Direct-acting antivirals for acute HCV: how short can we go?

J. Grebely, M. Martinello, G. Matthews, 2017, The lancet. Gastroenterology & hepatology.

High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.

M. Alavi, G. Dore, M. Law, 2020, Journal of hepatology.

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials

T. Asselah, F. Negro, B. Conway, 2019, Liver international : official journal of the International Association for the Study of the Liver.

A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.

G. Dore, J. Grebely, A. Lloyd, 2023, Journal of hepatology.

Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study

C. Treloar, J. Grebely, A. Conway, 2023, Implementation Science.

Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study.

P. Read, G. Dore, L. Degenhardt, 2023, Drug and alcohol review.

Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar

J. Grebely, T. Applegate, S. Phyu, 2023, Viruses.

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection

D. Booth, T. Berg, G. Ahlenstiel, 2013, Genes and Immunity.

1063 FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION

M. Hellard, G. Dore, M. Prins, 2010 .

Reinfection incidence and risk among people treated for recent hepatitis C virus infection

M. Hellard, J. Rockstroh, G. Dore, 2023, AIDS.

Hepatitis C care cascade before and during the direct‐acting antiviral eras in New South Wales, Australia: A population‐based linkage study

M. Alavi, G. Dore, J. Grebely, 2022, Journal of viral hepatitis.

Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study

M. Alavi, G. Dore, J. Amin, 2020, Journal of Hepatology.

A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.

G. Ahlenstiel, J. George, S. Locarnini, 2014, Gastroenterology.

Edinburgh Research Explorer Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C

M. Alavi, G. Dore, H. Innes, 2017 .

Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection

J. Kaldor, D. Booth, M. Hellard, 2010, Hepatology.

Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis.

M. Hellard, G. Dore, M. van der Valk, 2023, The Lancet. Microbe.

hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data

M. Hellard, E. McBryde, J. Grebely, 2014 .

P762 TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADA

J. Montaner, J. Joy, G. Dore, 2014 .

Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

M. Alavi, G. Dore, M. Law, 2016, Journal of hepatology.

Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.

M. Alavi, G. Dore, M. Law, 2016, Journal of hepatology.

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.

Jisoo A. Kwon, R. Malekzadeh, F. Tacke, 2023, The lancet. Gastroenterology & hepatology.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

S. Alavian, M. Manns, Chien-Jen Chen, 2017, The lancet. Gastroenterology & hepatology.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

J. Lazarus, M. Hellard, G. Dore, 2017, The International journal on drug policy.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

M. Hellard, J. Grebely, P. Bruggmann, 2015, The International journal on drug policy.

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.

G. Dore, J. Grebely, L. Maher, 2017, The International journal on drug policy.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

G. Dore, D. Persing, J. Amin, 2017, The lancet. Gastroenterology & hepatology.

Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.

M. Alavi, G. Dore, P. Haber, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011

H. Wand, G. Dore, J. Grebely, 2014, Journal of viral hepatitis.

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection

J. Kaldor, M. Hellard, G. Dore, 2012, Hepatology.

Correction: Alexander Technique Lessons or Acupuncture Sessions for Persons With Chronic Neck Pain

G. Dore, L. Taylor, J. Grebely, 2016, Annals of Internal Medicine.

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

M. Alavi, J. Kaldor, M. Hellard, 2015, The International journal on drug policy.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

M. Hellard, G. Dore, K. Petoumenos, 2016, Hepatology.

On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study

A. Mangia, X. Forns, G. Dore, 2016 .

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study

C. Stedman, G. Cooke, G. Dore, 2023, JHEP reports : innovation in hepatology.

Prioritization of HCV treatment in the direct-acting antiviral era: An evaluation.

G. Dore, P. Vickerman, M. Hickman, 2017 .

The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure.

G. Dore, J. Grebely, G. Matthews, 2008, Journal of hepatology.

Health utility among people who regularly use opioids in Australia.

B. Larance, L. Degenhardt, J. Grebely, 2024, Drug and alcohol review.

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

B. Larance, J. Grebely, M. Montebello, 2024, International Journal of Drug Policy.

Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons

J. Grebely, B. Hajarizadeh, Yumi Sheehan, 2024, International Journal of Drug Policy.

Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study

P. Vickerman, J. Grebely, B. Hajarizadeh, 2023, Journal of viral hepatitis.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

B. Conway, M. Hellard, G. Dore, 2017, The International journal on drug policy.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

J. Grebely, R. Sacks-Davis, J. Schinkel, 2015, Journal of viral hepatitis.

Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection

J. Kaldor, M. Hellard, G. Dore, 2013, Hepatology.

Abstracts of the Australasian Viral Hepatitis Elimination Conference: poster presentations

C. Treloar, J. Grebely, D. Anderson, 2017, Journal of Virus Eradication.

Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia

M. Alavi, J. Grebely, B. Hajarizadeh, 2024, The Lancet Regional Health - Western Pacific.

Patterns of drug use among people who inject drugs: A global systematic review and meta-analysis.

J. Leung, J. Grebely, Samantha Colledge-Frisby, 2024, The International journal on drug policy.

Joint statement in support of hepatitis C human challenge studies.

Daniel M. Haybron, S. Pinker, G. Lauer, 2023, The lancet. Gastroenterology & hepatology.

Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.

J. Grebely, B. Hajarizadeh, Samantha Colledge, 2024, The lancet. Gastroenterology & hepatology.

Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis.

J. Grebely, B. Hajarizadeh, L. Tran, 2024, The Lancet. Public health.

Effect of incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection drug use-associated bacterial infections: A self-controlled case series in New South Wales, Australia.

L. Degenhardt, J. Grebely, D. Lewer, 2023, The International journal on drug policy.

Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study

J. Grebely, M. Byrne, Y. Sheehan, 2024, The Lancet Regional Health - Western Pacific.